NCT04639219 - A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

January 25, 2023

Study Completion Date

July 14, 2026

Conditions

Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

Interventions

DRUG

Trastuzumab deruxtecan

Trastuzumab deruxtecan (T-DXd) by intravenous infusion

Trial Locations (30)

1070

Research Site, Anderlecht

2100

Research Site, Copenhagen

10021

Research Site, New York

10604

Research Site, Harrison

11725

Research Site, Commack

20141

Research Site, Milan

20162

Research Site, Milan

22031

Research Site, Fairfax

28041

Research Site, Madrid

28050

Research Site, Madrid

31008

Research Site, Pamplona

33076

Research Site, Bordeaux

41013

Research Site, Seville

47303

Research Site, Muncie

69008

Research Site, Lyon

77030

Research Site, Houston

80131

Research Site, Napoli

94805

Research Site, Villejuif

95403

Research Site, Santa Rosa

02115

Research Site, Boston

02215

Research Site, Boston

07748

Research Site, Middletown

M5G 2M9

Research Site, Toronto

104-0045

Research Site, Chūōku

277-8577

Research Site, Kashiwa

565-0871

Research Site, Suita-shi

03080

Research Site, Seoul

03722

Research Site, Seoul

06351

Research Site, Seoul

08035

Research Site, Barcelona